Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Asmat Ullah Khan, Muhammad Akram, Muhammad Daniyal & Rida Zainab. (2019) Awareness and current knowledge of Parkinson’s disease: a neurodegenerative disorder. International Journal of Neuroscience 129:1, pages 55-93.
Read now
Read now
Thomas Müller. (2017) Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease. Expert Opinion on Pharmacotherapy 18:14, pages 1457-1465.
Read now
Read now
Giulio Lancioni, Nirbhay Singh, Mark O'Reilly, Jeff Sigafoos, Fiora D'Amico, Giovanni Sasanelli, Floriana Denitto & Russell Lang. (2016) Technology-aided leisure and communication: Opportunities for persons with advanced Parkinson’s disease. Developmental Neurorehabilitation 19:6, pages 398-404.
Read now
Read now
Articles from other publishers (23)
Carlos Trenado, Nicole Pedroarena-Leal, Laura Cif & Diane Ruge. (2023) Electrophysiological variability as marker of dystonia worsening under deep brain stimulation successive withdrawal and renewal effects. European Journal of Paediatric Neurology.
Crossref
Crossref
Xiao-Zhong Jing, Xiang-Zhen Yuan, Xingguang Luo, Shu-Yun Zhang & Xiao-Ping Wang. (2023) An Update on Nondopaminergic Treatments for Motor and Non-motor
Symptoms of Parkinson’s Disease. Current Neuropharmacology 21:8, pages 1806-1826.
Crossref
Crossref
Komal Latif, Aman Ullah, Anastasiia D. Shkodina, Dmytro I. Boiko, Zakia Rafique, Badrah S. Alghamdi, Mohamed A. Alfaleh & Ghulam Md. Ashraf. (2022) Drug reprofiling history and potential therapies against Parkinson’s disease. Frontiers in Pharmacology 13.
Crossref
Crossref
Ritam Bandopadhyay, Nainshi Mishra, Ruhi Rana, Gagandeep Kaur, Mohammed M. Ghoneim, Sultan Alshehri, Gulam Mustafa, Javed Ahmad, Nabil. A. Alhakamy & Awanish Mishra. (2022) Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence. Frontiers in Pharmacology 13.
Crossref
Crossref
Agnieszka A. Kaczor, Karolina Wojtunik-Kulesza, Tomasz M. Wróbel, Dariusz Matosiuk & Monika Pitucha. (2022) 5-Methoxy-1-methyl-2-{[4-(2-hydroxyphenyl)piperazin-1-yl]methyl}-1Hindole (KAD22) with Antioxidant Activity. Letters in Organic Chemistry 19:4, pages 263-275.
Crossref
Crossref
Thomas Müller. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
2853
2870
.
Carlos Trenado, Laura Cif, Nicole Pedroarena-Leal & Diane Ruge. (2021) Electrophysiological Signature and the Prediction of Deep Brain Stimulation Withdrawal and Insertion Effects. Frontiers in Neurology 12.
Crossref
Crossref
Srijan Acharya & Kyeong-Man Kim. (2021) Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease. International Journal of Molecular Sciences 22:9, pages 4299.
Crossref
Crossref
Robert G. Briggs, Syed A. Ahsan, Andrew K. Conner, Cameron E. Nix, Christina C. Jacobs, Ryan G. Jones, John R. Sheets, Ali H. Palejwala, Kassem Chendeb & Michael E. Sughrue. (2020) Neurochemical supplementation in patients with depressed levels of participation after brain tumor surgery: Rationale and preliminary results. Journal of Clinical Neuroscience 71, pages 93-96.
Crossref
Crossref
Bárbara Mendes-Pinheiro, Ana Marote, Cláudia R. Marques, Fábio G. Teixeira, Jorge Cibrão Ribeiro & António J. Salgado. 2020. Mesenchymal Stem Cells in Human Health and Diseases. Mesenchymal Stem Cells in Human Health and Diseases
79
114
.
Thomas Müller. 2019. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy
1
18
.
Maulana Ikhsan, Alex Palumbo, Dorothee Rose, Marietta Zille & Johannes Boltze. (2019) Neuronal Stem Cell and Drug Interactions: A Systematic Review and Meta-Analysis: Concise Review. Stem Cells Translational Medicine 8:11, pages 1202-1211.
Crossref
Crossref
Eugeniy Demianenko, Alexey Rayevsky, Marvin A. Soriano-Ursúa & José G. Trujillo-Ferrara. (2019) Theoretical Coupling and Stability of Boronic Acid Adducts with Catecholamines. Letters in Drug Design & Discovery 16:4, pages 467-475.
Crossref
Crossref
Maryka Quik, James T Boyd, Tanuja Bordia & Xiomara Perez. (2019) Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders. Nicotine & Tobacco Research 21:3, pages 357-369.
Crossref
Crossref
Carlos Trenado, Matthias Boschheidgen, Julia Rübenach, Karim N’Diaye, Alfons Schnitzler, Luc Mallet & Lars Wojtecki. (2018) Assessment of Metacognition and Reversal Learning in Parkinson’s Disease: Preliminary Results. Frontiers in Human Neuroscience 12.
Crossref
Crossref
Fábio G. Teixeira, Miguel F. Gago, Paulo Marques, Pedro Silva Moreira, Ricardo Magalhães, Nuno Sousa & António J. Salgado. (2018) Safinamide: a new hope for Parkinson’s disease?. Drug Discovery Today 23:3, pages 736-744.
Crossref
Crossref
T. Shen, R. Ye & B. Zhang. (2017) Efficacy and safety of pramipexole extended‐release in Parkinson's disease: a review based on meta‐analysis of randomized controlled trials. European Journal of Neurology 24:6, pages 835-843.
Crossref
Crossref
S Mehan, G Kaur, R Dudi, M Rajput & S Kalra. (2017) Restoration of Mitochondrial Dysfunction in 6-Hydroxydopamine Induced Parkinson’s disease: a Complete Review. Open Journal of Parkinson's Disease and Treatment 1:1, pages 001-026.
Crossref
Crossref
Mark R. Cookson. 2017. Disease-Modifying Targets in Neurodegenerative Disorders. Disease-Modifying Targets in Neurodegenerative Disorders
157
174
.
Thomas Müller. (2016) Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective. Neurodegenerative Disease Management 6:5, pages 385-398.
Crossref
Crossref
Dhanya Vijayakumar & Joseph Jankovic. (2016) Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs 76:7, pages 759-777.
Crossref
Crossref
Antonio Daniele, Francesco Panza, Antonio Greco, Giancarlo Logroscino & Davide Seripa. (2016) Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson’s Disease? The Potential Role of Zolpidem in the Treatment of Parkinson’s Disease. Parkinson's Disease 2016, pages 1-14.
Crossref
Crossref
Maryka Quik, Danhui Zhang, Matthew McGregor & Tanuja Bordia. (2015) Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease. Biochemical Pharmacology 97:4, pages 399-407.
Crossref
Crossref